Program
Bortezomib
Also written as “bortezomib”, “VELCADE” and “VELCADE TM (bortezomib) for Injection”.
Its studies are mostly in Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Lymphoma, Mantle-Cell · Lymphoma, Follicular · Amyloidosis, led by 6 companies.
Drug pageBortezomib: every studyMany companies study it; this page follows only the 62 they lead. All 651 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 285 open or running | phase 4since Oct 15, 2014 | Sep 13, 2005 | Feb 14, 2029phase 3 · NCT04923893 |
| Takedaits history only | 250 open or running | phase 4since Nov 18, 2005 | Oct 28, 2002 | none ahead |
| Oncotherapeuticsits history only | 40 open or running | phase 2since Apr 24, 2006 | Apr 19, 2006 | none ahead |
| AbbVieits history only | 32 open or running | phase 3since Nov 28, 2023 | Aug 19, 2016 | Dec 2027phase 3 · NCT06158841 |
| AstraZenecaits history only | 10 open or running | phase 4since Aug 23, 2023 | Aug 23, 2023 | none ahead |
| Clinical Service, Chinaits history only | 10 open or running | phase 2since Mar 29, 2011 | Mar 29, 2011 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jan 21, 2003.
- Oct 15, 2014Phase 4 study in Multiple MyelomaJohnson & Johnson · NCT02268890 · 18 enrolled · Taiwan
- May 26, 2016Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT02811978 · 81 enrolled · China
- Aug 1, 2016Phase 2 study in Multiple MyelomaJohnson & Johnson · NCT02874742 · 224 enrolled · United States
- Aug 19, 2016AbbVie’s first study: phase 2 study in Multiple MyelomaNew to AbbVieAbbVie · NCT02902965 · 74 enrolled · Czechia, Germany, Greece and more
- Oct 31, 2016Phase 2 study in Multiple MyelomaJohnson & Johnson · NCT02951819 · 101 enrolled · United States
- Oct 11, 2017Phase 2 study in Multiple MyelomaAbbVie · NCT03314181 · 156 enrolled · United States, Australia, Canada and more
- Nov 27, 2019Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT04181827 · 419 enrolled · United States, Australia, Belgium and more
- Jun 10, 2021Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT04923893 · 743 enrolled · United States, Argentina, Australia and more
- Oct 8, 2021Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT05083169 · 587 enrolled · United States, Argentina, Belgium and more
- Sep 30, 2022Phase 2 study in Lymphoma, Mantle-CellJohnson & Johnson · NCT05564052 · 36 enrolled · Brazil, Czechia, Greece and more
- Oct 5, 2022Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT05572515 · 614 enrolled · United States, Australia, Austria and more
- Aug 23, 2023AstraZeneca’s first study: phase 4 study in HypophosphatasiaNew to AstraZenecaAstraZeneca · NCT06015750
- Nov 28, 2023Phase 3 study in Multiple MyelomaAbbVie · NCT06158841 · 421 enrolled · United States, Australia, Austria and more
- Aug 27, 2024Phase 2 study in Multiple MyelomaJohnson & Johnson · NCT06577025 · 43 enrolled · United States, Australia, Brazil and more
Ahead
- Dec 2027Primary completion: phase 3 study in Multiple MyelomaAbbVie · NCT06158841
- Feb 14, 2029Primary completion: phase 3 study in Multiple MyelomaJohnson & Johnson · NCT04923893
- Sep 2, 2030Primary completion: phase 2 study in Multiple MyelomaJohnson & Johnson · NCT06577025
- May 2031Primary completion: phase 2 study in Multiple MyelomaAbbVie · NCT03314181
TargetBeta
“26S proteasome inhibitor; 26S proteasome inhibitor”ChEMBL 37, by rule
Other programs on the same 38 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| carfilzomibrule | Amgen | phase 4 | 38 |
Studies
The newest 60 of 62 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06577025Multiple Myeloma · United States, Australia, Brazil and more | 2 | Active, not recruiting | Johnson & Johnson | Sep 2, 2030 | 43 |
| NCT06158841Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | AbbVie | Dec 2027 | 421 |
| NCT06015750Hypophosphatasia | 4 | Withdrawn | AstraZeneca | Mar 13, 2030 | 0 |
| NCT05572515Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | Johnson & Johnson | Oct 13, 2025 | 614 |
| NCT05564052Lymphoma, Mantle-Cell · Brazil, Czechia, Greece and more | 2 | Completed | Johnson & Johnson | Dec 6, 2023 | 36 |
| NCT05083169Multiple Myeloma · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | Aug 1, 2025 | 587 |
| NCT04923893Multiple Myeloma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Feb 14, 2029 | 743 |
| NCT04181827Multiple Myeloma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | May 1, 2024 | 419 |
| NCT03314181Multiple Myeloma · United States, Australia, Canada and more | 2 | Active, not recruiting | AbbVie | May 2031 | 156 |
| NCT02951819Multiple Myeloma · United States | 2 | Completed | Johnson & Johnson | Mar 8, 2018 | 101 |
| NCT02902965Multiple Myeloma · Czechia, Germany, Greece and more | 2 | Completed | AbbVie | Oct 26, 2018 | 74 |
| NCT02874742Multiple Myeloma · United States | 2 | Completed | Johnson & Johnson | Jan 25, 2019 | 224 |
| NCT02811978Multiple Myeloma · China | 3 | Completed | Johnson & Johnson | May 7, 2018 | 81 |
| NCT02268890Multiple Myeloma · Taiwan | 4 | Completed | Johnson & Johnson | Jul 2015 | 18 |
| NCT01902862Lymphoma, Follicular · Germany | 2 | Terminated | Johnson & Johnson | Aug 2007 | 7 |
| NCT01801436Multiple Myeloma | 3 | Completed | Johnson & Johnson | Apr 2008 | 14 |
| NCT01910987Multiple Myeloma · Belgium, Finland, France and more | 3 | Completed | Johnson & Johnson | Feb 2016 | 80 |
| NCT01695330Multiple Myeloma · United States | 2 | Terminated | Oncotherapeutics | Oct 2015 | 5 |
| NCT01539083Multiple Myeloma · Australia, China, Korea, Republic of | 3 | Completed | Johnson & Johnson | Dec 30, 2015 | 256 |
| NCT01328236Leukemia, Plasma Cell · China | 2 | UNKNOWN | Clinical Service, China | Sep 2013 | 20 |
| NCT01286077Multiple Myeloma · Austria, Czech Republic, Denmark and more | 2 | Completed | Johnson & Johnson | Nov 2012 | 106 |
| NCT01040871Lymphoma, Large B-Cell, Diffuse · Belgium | 2 | Completed | Takeda | Jun 2012 | 164 |
| NCT00985959Multiple Myeloma · Japan | 1 | Completed | Johnson & Johnson | Jun 2010 | 101 |
| NCT00931918Acromesomelic dysplasia, Maroteaux type · United States | 2 | Completed | Takeda | Aug 2015 | 206 |
| NCT00908232Multiple Myeloma · France, Germany, Greece and more | 2 | Completed | Johnson & Johnson | Aug 2011 | 163 |
| NCT00850499Lymphoma, Follicular · France, Germany, Greece and more | 2 | Terminated | Takeda | Sep 2011 | 12 |
| NCT00833560Multiple Myeloma · Germany | 2 | Completed | Johnson & Johnson | Jun 2009 | 401 |
| NCT00813150Multiple Myeloma · Germany | 3 | Completed | Johnson & Johnson | Jan 2013 | 96 |
| NCT00752518Multiple Myeloma | 2 | Completed | Johnson & Johnson | 35 | |
| NCT00742404Multiple Myeloma · United States | 2 | UNKNOWN | Oncotherapeutics | Jul 2010 | 35 |
| NCT00722137Lymphoma, Mantle-Cell · United States, Austria, Belgium and more | 3 | Completed | Takeda | Jan 1, 2014 | 487 |
| NCT00718640Multiple Myeloma · Canada | 2 | Terminated | Johnson & Johnson | Dec 2009 | 10 |
| NCT00715208Lymphoma, Follicular · United States, Puerto Rico | 2 | Completed | Takeda | Feb 2011 | 55 |
| NCT00706953Multiple Myeloma | 2 | Withdrawn | Johnson & Johnson | Jun 2010 | 0 |
| NCT00610792Ovarian Neoplasms · Italy, Switzerland | 2 | Withdrawn | Takeda | Sep 2009 | 91 |
| NCT00608907Multiple Myeloma · Israel, Italy, Poland and more | 1 | Completed | Takeda | Mar 2010 | 61 |
| NCT00561743Multiple Myeloma | 2 | Completed | Johnson & Johnson | May 2007 | 50 |
| NCT00531453Multiple Myeloma · Austria | 2 | Completed | Takeda | Apr 2009 | 98 |
| NCT00441168Multiple Myeloma · Croatia, Germany, Hungary and more | 2 | Terminated | Johnson & Johnson | Jan 2008 | 30 |
| NCT00431769Multiple Myeloma · Austria, Belgium, France and more | 2 | Completed | Johnson & Johnson | Feb 2009 | 130 |
| NCT00416273Multiple Myeloma · Germany | 3 | Completed | Johnson & Johnson | May 2013 | 217 |
| NCT00416208Multiple Myeloma · Germany | 3 | Completed | Johnson & Johnson | May 2013 | 154 |
| NCT00343720Carcinoma, Non-Small-Cell Lung · Belgium | 2 | Completed | Takeda | Oct 2007 | |
| NCT00317811Multiple Myeloma · United States | 2 | Completed | Oncotherapeutics | Feb 2009 | 35 |
| NCT00316940Multiple Myeloma · United States | 1 | Completed | Oncotherapeutics | Jun 2008 | 36 |
| NCT00312845Lymphoma, Non-Hodgkin · United States, Argentina, Australia and more | 3 | Completed | Takeda | Jun 2010 | 676 |
| NCT00298766Amyloidosis · United States | 2 | Completed | Takeda | Jul 2009 | 70 |
| NCT00283634NSCLC · United States | 2 | Terminated | Takeda | Jul 2007 | |
| NCT00257114Multiple Myeloma · United States | 4 | Completed | Takeda | Mar 2007 | |
| NCT00216697Multiple Myeloma | 2 | Completed | Johnson & Johnson | 13 | |
| NCT00129207Neoplasms · United States | 1 | Completed | Takeda | Sep 2006 | |
| NCT00117351Carcinoma, Non-Small-Cell Lung · United States | 2 | Terminated | Takeda | Jun 2007 | |
| NCT00111319Multiple Myeloma · United States | 3 | Completed | Takeda | Jul 2007 | |
| NCT00085696Lymphoma, B-Cell · United States | 2 | Completed | Takeda | Apr 2006 | 66 |
| NCT00080405Multiple Myeloma | 1 | Completed | Takeda | Jun 2005 | 40 |
| NCT00064636Advanced Non-Small Cell Lung Cancer | 1 | Terminated | Takeda | 46 | |
| NCT00064610Prostatic Neoplasms · United States | 2 | Completed | Takeda | Dec 2004 | 102 |
| NCT00063726Multiple Myeloma · United States, Austria, Belgium and more | 3 | Completed | Takeda | May 2005 | 600 |
| NCT00063713Lymphoma, Mantle-Cell · United States | 2 | Completed | Takeda | Dec 2005 | 152 |
| NCT00051987Colorectal Neoplasms · United States | 2 | Completed | Takeda | Mar 2004 | 175 |
How it is read
Names in the registry
- “Bortezomib”, 42 entries
- “bortezomib”, 18 entries
- “VELCADE”, 6 entries
- “VELCADE TM (bortezomib) for Injection”, 2 entries
- “VELCADE TM (bortezomib) for Injection, or PS-341”, 2 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 61 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Lymphoma, Mantle-Cell, 3 studies
- Lymphoma, Follicular, 3 studies
- Amyloidosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.